

Jawed, R. . (2025). Association of anti-BCOADC-E2 autoantibodies with increased bilirubin levels in Chinese primary biliary cholangitis patients. *Biomedical Research and Therapy*, 12(7), 7529-7536. <https://doi.org/10.15419/92fgv495>


## Supplementary Material

**Supplementary Table 1** Baseline characteristics of PBC Patients (n=780)

General Characteristic	Results	Reference value
Age	55.9 ± 11.3	
Sex (Female/male)	666/114	
TB	45.4 ± 65.1	3-22 µmol/L
DB	29.0 ± 51.0	1-10 µmol/L
Cholesterol	5.5 ± 2.7	3-6 mmol/L
ALT	124.2 ± 210.8	1-40 U/L
AST	120.4 ± 179.0	1-40 U/L
GGT	361.0 ± 310.0	3-50 U/L
ALP	336.4 ± 220.0	40-150 U/L
TP	73.7 ± 10.1	65-85 g/L
ALB	37.9 ± 7.2	35-55 g/L


ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; TB: total bilirubin; DB: direct bilirubin; TP: total protein; ALB: albumin. Values are mean ± SD.

**Supplemental Figure S1** Titers analysis of anti-PDC-E2 during the UDCA treatment.



**Supplemental Figure S1** Titers analysis of anti-PDC-E2 during the UDCA treatment. Serum samples of the same patients were collected at different time points during UDCA treatment. A series of dilution of each serum sample at different time point were analyzed in triplicates in the same plate per antibody. OD<sub>450</sub> value of serum samples of ten PBC patients before (0 month) and after UDCA treatment were plotted against the time after treatment (months). Each sample was analyzed in duplicates or triplicates. Data are represented as mean  $\pm$  SD.

**Supplemental Figure S2** Titers analysis of anti-OGDC-E2 during the UDCA treatment.



**Supplemental Figure S2** Titers analysis of anti-OGDC-E2 during the UDCA treatment. Serum samples of the same patients were collected at different time points during UDCA treatment. A series of dilution of each serum sample at different time point were analyzed in triplicates in the same plate per antibody. OD<sub>450</sub> value of serum samples of ten PBC patients before (0 month) and after UDCA treatment were plotted against the time after treatment (months). Each sample was analyzed in duplicates or triplicates. Data are represented as mean  $\pm$  SD.